Abstract:DNA methyltransferase 1 (DNMT1) is the primary enzyme responsible for maintaining DNA methylation patterns during cellular division, crucial for cancer development by suppressing tumor suppressor genes. In this study, we retained the phthalimide structure of N -phthaloyl-L-tryptophan (RG108) and substituted its indole ring with nitrogen-containing aromatic rings of varying sizes. We synthesized 3-(9 H -carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acids and confirmed them as DNMT1 inhibitors through protein affinity testing, radiometric method using tritium labeled SAM, and MTT assay. Preliminary structure-activity relationship analysis revealed that introducing substituents on the carbazole ring could enhance inhibitory activity, with S -configuration isomers showing greater activity than R -configuration ones. Notably, S -3-(3,6-di- tert -butyl-9 H -carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acid ( 7r- S ) and S -3-(1,3,6-trichloro-9 H -carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acid ( 7t- S ) exhibited significant DNMT1 enzyme inhibition activity, with IC 50 values of 8.147 μM and 0.777 μM, respectively (compared to RG108 with an IC 50 above 250 μM). Moreover, they demonstrated potential anti-proliferative activity on various tumor cell lines including A2780, Hela, K562, and SiHa. Transcriptome analysis and KEGG pathway enrichment of K562 cells treated with 7r- S and 7t- S identified differentially expressed genes (DEGs) related to apoptosis and cell cycle pathways. Flow cytometry assays further indicated that 7r- S and 7t- S induce apoptosis in K562 cells and arrest them in the G0/G1 phase in a concentration-dependent manner. Molecular docking revealed that 7t- S may bind to the methyl donor S -adenosyl-l-methionine (SAM) site in DNMT1 with an orientation opposite to RG108, suggesting potential for deeper penetration into the DNMT1 pocket and laying the groundwork for further modifications.

Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells.

Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors.

Discovery of novel non-nucleoside inhibitors with high potency and selectivity for DNA methyltransferase 3A

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors Through Docking-Based Virtual Screening.

Targeting DNA methyltransferases for cancer therapy

Progress in combined treatments of myelodysplastic syndrome and acute myeloid leukemia based on DNA methyltransferase inhibitors

DNA Methyltransferase Inhibitors and Their Therapeutic Potential.

DNA Methyltransferase Inhibitors and Their Therapeutic Potential

Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy

Supercomputer-Based Virtual Screening for Deoxyribonucleic Acid Methyltransferase 1 Inhibitors as Novel Anticancer Agents

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Differential induction of apoptosis and senescence by the DNA methyltransferase inhibitors 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumor cells

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Do Anticancer Medicinal Compounds have DNMT1 Regulating Activity: An In silico Investigation

DNA Methyltransferases: A Novel Target for Prevention and Therapy

Identification of 3-(9 H -carbazol-9-yl)-2-(1,3-dioxoisoindolin-2-yl)propanoic acids as promising DNMT1 inhibitors

Fragment-based discovery of new potential DNMT1 inhibitors integrating multiple pharmacophore modeling, 3D-QSAR, virtual screening, molecular docking, ADME, and molecular dynamics simulation approaches

Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy

Design, synthesis and antitumor evaluations of nucleoside base hydroxamic acid derivatives as DNMT and HDAC dual inhibitors

Triptolide sensitizes cancer cells to nucleoside DNA methyltransferase inhibitors through inhibition of DCTPP1-mediated cell-intrinsic resistance